Kerri Fitzgerald

DocwireNews

An experimental cancer vaccine&nbsp;plus immunotherapy ( Diprovocim) demonstrated&nbsp;a 100%&nbsp;survival&nbsp;rate in&nbsp;mice with melanoma, according to a study&nbsp;published in&nbsp;Proceedings of the National Academy of Sciences.&nbsp;&nbsp;The researchers tested the vaccine on mice with aggressive melanoma. All mice&nbsp;received&nbsp;anti-PD-L1&nbsp;therapy and were divided&nbsp;into three group:&nbsp;&nbsp;<ol>
<li>some received the vaccine (n=8)&nbsp;</li>
<li>some received the vaccine plus&nbsp;Diprovocim,&nbsp;which&nbsp;targets the innate immune receptor TLR1/TLR2 in mice and humans&nbsp;(n=8)&nbsp;&nbsp;</li>
<li>and some received the vaccine plus an alternative adjuvant, alum (n=8)&nbsp;</li>
</ol>Among the mice who received the vaccine and&nbsp;Diprovocim, there was a&nbsp;100 percent survival rate after&nbsp;54 days.&nbsp;There was a zero&nbsp;percent survival rate in mice given only the cancer vaccine and a 25 percent survival rate in mice given the cancer vaccine with alum.&nbsp;When the researchers tried to re-establish the tumors in the mice&nbsp;who received the vaccine plus&nbsp;Diprovocim, it did not take.&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
A New Cancer Vaccine Shown to Be 100% Effective in Mice With Aggressive Melanoma <a href="https://t.co/advMEjZSe8">https://t.co/advMEjZSe8</a>
&mdash; Pediatric Academic Societies (@PASMeeting) <a href="https://twitter.com/PASMeeting/status/1039503948674162688?ref_src=twsrc%5Etfw">September 11, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>&ldquo;This co-therapy produced a complete response&mdash;a curative response&mdash;in the treatment of melanoma,&rdquo;&nbsp;said&nbsp;Dale Boger, PhD,&nbsp;co-leader of the study.&nbsp;&nbsp;The researchers noted that&nbsp;Diprovocim&nbsp;is easy to synthesize in the lab and easy to modify.&nbsp;In addition, the vaccine was not injected directly into the tumor, which the researchers called &ldquo;encouraging.&rdquo;&nbsp;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
A New Cancer Vaccine Shown to Be 100% Effective in Mice With Aggressive Melanoma <a href="https://t.co/pdZ3VgdxOi">https://t.co/pdZ3VgdxOi</a>
&mdash; ScienceAlert (@ScienceAlert) <a href="https://twitter.com/ScienceAlert/status/1039425819200905216?ref_src=twsrc%5Etfw">September 11, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>The researchers plan to conduct more preclinical studies to assess the vaccine with other anti-cancer medications.&nbsp;<a href="https://proddocwire.wpengine.com/docwire-pick/a-simple-blood-test-for-melanoma-detection/">Read more about a simple blood test for melanoma detection.</a>&nbsp;<a href="https://proddocwire.wpengine.com/docwire-pick/melanoma-brain-metastases/">Study identifies combination therapy for melanoma-related brain metastases.</a>&nbsp;Source:&nbsp;<a href="http://www.pnas.org/content/early/2018/08/22/1809232115.short?rss=1">Proceedings of the National Academy of Sciences&nbsp;</a>

Jordana Jampel

Positive Preliminary Results From Phase 1 Trial of Dopaminergic Neuron Graft for Parkinson’s Disease

Dementia

Bradley Warady, MD

Joel M. Topf, MD, FACP

2025 Hume Award Winner Is Dedicated to Children’s Care

NKF Spring Clinical Meetings 2025

Distant Brain Metastases in Cutaneous Melanoma May Be Mitigated With Multiple Pathway Inhibitors

Melanoma

Latest News

New Cancer Vaccine is 100% Effective in Mice With Aggressive Melanoma

Skin Cancer

An experimental cancer vaccine plus immunotherapy ( Diprovocim) demonstrated a 100% survival rate in mice with melanoma, according to a study published in Proceedings ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe